Objective: Describe the prevalence of the anticholinergic drugs (AD) used in patients who consult in regard to loss of memory. Assess the cognitive and functional repercussion of these drugs.
Patients and methods: Retrospective review of the clinic history of the patients who consulted the clinic in 2015 and 2016. We used the Anticholinergic Cognitive Burden Scale. We explored cognition with the Mini Mental State Examination (MMSE) and function with the Barthel Index and the Lawton and Brody Scale. We compared the difference of scale scores between the patients exposed and not exposed to AD.
Results: Sample size of 610 patients (mean age=81.1years), 71% female. 37.2% of patients took AD. The mean (SD) difference between exposed and not exposed patients and the year-on-year worsening rate of the Barthel Index and the Lawton and Brody Scale and MMSE were -4 (4.5), -0.3 (0.4) and -1 (0.9), respectively.
Conclusions: One third of patients who consulted for cognitive loss are taking AD. Patients exposed to AD show a greater tendency to impairment.
Keywords: Antagonistas colinérgicos; Cholinergic antagonists; Cognición; Cognition; Demencia; Dementia; Polifarmacia; Polypharmacy.
Copyright © 2018 Elsevier España, S.L.U. All rights reserved.